SCHEMBL5459980

SCHEMBL5459980

COc1ccccc1NC(=O)Nc1ccc(C2CCN(C(=O)Nc3ncccc3C)CC2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 1/20 0.62
RAB9A P51151 8/20 0.50
NPC1 O15118 7/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
MAPT P10636 5/20 0.49
LMNA P02545 3/20 0.49
HTT P42858 2/20 0.49
TP53 P04637 1/20 0.49
KDM4E B2RXH2 4/20 0.48
USP2 O75604 1/20 0.48
ALDH1A1 P00352 1/20 0.48
TSHR P16473 1/20 0.48
HSD17B10 Q99714 1/20 0.48
ATM Q13315 1/20 0.47
TRPV1 Q8NER1 1/20 0.47
POLB P06746 1/20 0.46
PKM P14618 1/20 0.46
MAPK1 P28482 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5460565 0.91 MAPT (0.49) GFERRAB9ANPC1SMN1; SMN2MAPT
SCHEMBL5456044 0.88 GFER (0.46) GFERRAB9ANPC1SMN1; SMN2MAPT
SCHEMBL5464796 0.88 RAB9A (0.57) GFERRAB9ANPC1SMN1; SMN2MAPT
SCHEMBL5470995 0.88 RAB9A (0.51) GFERRAB9ANPC1SMN1; SMN2MAPT
SCHEMBL5459401 0.83 HSD17B10 (0.49) RAB9ANPC1SMN1; SMN2MAPTLMNA
SCHEMBL5462265 0.82 MAPT (0.48) RAB9ANPC1SMN1; SMN2MAPTLMNA
SCHEMBL5458373 0.82 RBP4 (0.48) RAB9ASMN1; SMN2MAPTLMNAHTT
SCHEMBL5451012 0.81 MAPT (0.47) RAB9ASMN1; SMN2MAPTLMNAHTT
SCHEMBL5473690 0.81 GFER (0.60) GFERRAB9ANPC1SMN1; SMN2MAPT
SCHEMBL5458362 0.81 RAB9A (0.58) RAB9ANPC1SMN1; SMN2MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 GFER 1367/4885RAB9A 1528/4885NPC1 1089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.